Epidemiology of Cancers in Zambia: A Significant Variation in Cancer Incidence and Prevalence across the Nation

Maybin Kalubula^{1,2*}, Heqing Shen^{1,2}, Mpundu Makasa³, Longjian Liu⁴

¹Key Lab of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China;

²University of Chinese Academy of Sciences, Beijing 100049, China;

³The University of Zambia, School of Medicine, Ridgeway Campus, P. O. Box 50110 Lusaka, Zambia.

⁴Drexel University, Dornsife School of Public Health, Chestnut Street 3141 Philadelphia, PA 19104 USA.

*Corresponding Authors:

Maybin Kalubula, Institute of Urban Environment, Chinese Academy of Sciences, 1799 Jimei Road, Xiamen 361021, China; Email address: <u>mkalubula@gmail.com</u>

Heqing Shen, Institute of Urban Environment, Chinese Academy of Sciences, 1799 Jimei Road, Xiamen 361021, China; Telephone/Fax: (86)-592-6190771; E-mail: <u>hqshen@iue.ac.cn</u>

ABSTRACT

Background

Cancers are one of the leading causes of death worldwide. More than two thirds of deaths due to cancers occur in low- and middle- income countries whereZambia belongs. This study therefore sought to assess the epidemiology of cancers in Zambia.

Methods

We conducted a retrospective observational study nested on Zambia National Cancer Registry (ZNCR) histopathological and clinical data from 2007 to 2014.Zambia Central Statistics Office (CSO)demographic datawere used to calculate prevalence and incidence rates of cancers. Ageadjusted rates and case fatality rates were estimated using standard methods. We used a Poisson Approximation for calculating 95% confidence intervals (CI).

Results

The top seven most cancer prevalent districts in Zambia have been Luangwa, Kabwe, Lusaka, Monze, Mongu, Katete and Chipata. Cervical cancer, prostate cancer, breast cancer and Kaposi's sarcoma were the top four most prevalent cancers as well as major causes of cancer related deaths in Zambia.Standardised Incidence Rates and 95% CI for the top four cancers were: cervix uteri (186.3; CI = 181.77 - 190.83), prostate (60.03; CI = 57.03 - 63.03), breast (38.08; CI = 36.0 - 40.16) and Kaposi's sarcoma (26.18; CI = 25.14 - 27.22).CFR were: Leukaemia (38.1%); pancreatic cancer (36.3%); lung cancer (33.3%); and brain, nervous system (30.2%). Cancers were associated with HIV with *p*-value of 0.000 and Pearson correlation coefficient of 0.818.

Conclusions

The widespread distribution of cancers with high prevalence in the southern zone has been perpetrated by lifestyle and sexual culture as well as geography. Intensifying cancer screening and early detection countrywide as well as changing the lifestyle and sexual culture would greatly help in the reduction of cancer cases in Zambia.

Keywords: Cancer epidemiology;Cervical cancer; Prostate cancer; Breast cancer, Kaposi's sarcoma; Cancers in Zambia;

INTRODUCTION

The global burden of cancers has been on the increase over the past few decades despite some remarkable advances in early cancer detection, treatment and prevention [1]. Cancers have continued to claim human lives and are one of the leading causes of death worldwide hence the realization by many organizations and researchers to make advancements inconventional medicine as well as anticancer nanomedicine and nanotechnology to broaden the spectrum of combating the scourge [2-4]. In the year 2013, cancers caused over 8 million deaths worldwide and have moved from the third leading cause of death in 1990 to the second leading cause behind cardiovascular diseases in 2013[5-7]. More than two thirds of deaths due to cancers occur in low-and middle- income countries [8].Low-income countries reported approximately 51% of all cancers globally in the year 1975 but this proportion steadily increased to 55% in 2007. It is estimated that by 2050, low-incomecountries will account for 61% of all cancers globally [9-11].

The global increase in the number of cancer cases is due to multiple factors such as lifestyle trends that are associated with economic development and the increasing adoption of risk behaviour such as consumption of unhealthy diets, lack of physical exercise, harmful use of alcohol and tobacco as well as exposures to environmental pollutants [12-15]. Thirdworld countries have 26% cancers attributable to infection while developed countries have 8% which is one third of cancers attributable to infection in thirdworld countries [16]. The oncogenic infections that have been linked to these cancers are Human Papilloma Virus (HPV) [17], Hepatitis B Virus (HBV) [18], *Helicobacter pylori* (*H. pylori*) [19], Human Herpes Virus (HHV8) [20], and Epstein Barr Virus (EBV) [21].

Although cancer incidence has been increasing in every part of the world, there are huge inequalities between developed and third world countries. Incidence rates remain highest in developed countries, but mortality is relatively much higher in third world countries due to lack of early detection and access to treatment facilities[8]. Infections due to human papillomavirus and hepatitis B and C viruses significantly contribute to the burden of cervical and liver cancers respectively on the African Continent [8]. The most common cancers in the African region are cervical, breast, liver and prostate as well as Kaposi's sarcoma and non-Hodgkin's lymphoma [8].

Zambia is one of the sub-Saharan African countries that have not been spared by the increasing burden of cancers. Many lives can be saved if appropriate investment is made in raising public awareness on the early signs and symptoms of common cancers as well as implementation of early detection strategies [8]. This study therefore sought to assess the epidemiology of cancers in Zambia with a view of finding amicable solution.

MATERIALS AND METHODS

Study site

The Republic of Zambia is located in the southern zone of the African continent and lies between latitudes 8° and 18° south, and longitudes 22° and 34° east. The country has a total geographical area of 753,612km² [22].

Study design

We conducted a retrospective observational study nested on Zambia National Cancer Registry (ZNCR) histopathological and clinical data from 2007 to 2014. ZNCR collects and keeps medical records of all diagnosed cancers in Zambia. The collected information include core variables such as patients personal details (names, age, sex, date of birth and residential address at diagnosis), hospital details (hospital, consultant patient unit number), diagnostics, tumour and treatment details (site of primary, morphology, laterality, stage, grade of tumour, basis of diagnosis, date of diagnosis, treatment indicators) and death details (alive or dead, date of death, cause(s) and place of death).

All health facilities countrywide submit reports of all diagnosed cancers to ZNCR. Medical records collected in form of hard copies are entered and stored in the ZNCR main database by data entry clerks. ZNCR ensures that cancer registrations data is stored securely, backed up and only accessible to authorised cancer registry staff. All cancer notification forms or books are filed and locked in a secure place. Information request for data on cancers are made in writing to the Registrar and the Permanent Secretary at the Ministry of Health for approval. This study was therefore approved by both the University of Zambia Biomedical Research Ethics Committee (UNZABREC) and the National Health Research Authority of Zambia.

Zambia Central Statistics Office (CSO) provided us with shapes files for provinces and districts as well as demographic data which we used to determine prevalence and Age-specific rates while World Standard Population [23] was used to determine Standardised Incidence Rates (SIR). *Case Fatality Rate (CFR)* = $\frac{\text{Deaths}}{\text{Cases}} \times 100$. We used a Poisson Approximation for calculating 95% confidence intervals. The 95% confidence interval for the age standardised rate is given by:

$RATE \pm 1.96 * \sqrt{var}$

Where the variance for the age standardised rate is given by: $\sum_{i} (\frac{p_i}{\sum p_i})^2 * \frac{r_i^2}{d_i}$ is the number of events in age group *i* in the study population

is the incidence rate in the study population for the persons in age group i \mathcal{P}_{i} is the number of persons in age group i in the standard population.

Mapping of the distribution of cancers at district and provincial levels were done using Geographical Information System (ArcGIS) version 10.3.1, Redlands, CA. Districts such as Ikelenge, Zimba and Mafinga were still part of the original districts namely, Mwinilunga, Kalomo and Isoka respectively during the study period hence we considered cancer rates of original districts in these new districts.

Sampling

Since our study was basically registry based, we considered all cancer cases in the Zambia National Cancer Registry database from 2007 to 2014. We however excluded cancer cases not belonging to any of the ten provinces in Zambia (i.e. not coded cases from any region in Zambia) for the purpose of GIS mapping which required that cancer cases be linked to districts and provinces of origin. In addition, we sampled and surveyed ten districts across Zambia to assess the cancer situation and determine some risk factors contributing to escalating cancer cases.

Statistical Analyses

We used SPSS version 21 in our data analyses. A linear regression model was used to determine the association between cancers and HIV while Pearson Correlation was used to determine the correlation coefficient. We used a Poisson Approximation for calculating 95% confidence intervals.

RESULTS

Distribution of cancers by region and province

Cancers are widely distributed in Zambiawith high prevalence concentrated in the southern zone comprising Eastern, Central, Lusaka, Western and Southern Provinces. The southern zone can be divided into high prevalence and medium prevalence regions. Eastern and Lusaka Provinces form the high prevalence region while Central, Southern and Western Provinces form the medium prevalence region. The northern zone comprising North Western, Copperbelt, Luapula, Northern and Muchinga Provinces has relatively low prevalence of cancers. **Figure 1** shows the distribution of all types of cancers in Zambia by region and province per 100,000 population.

By sex, cancers have been more prevalent in females than in males in all the ten provinces with mean sex ratio F/M = 1.85. Table 1 shows the prevalence of cancers by province and sex. Cancers in males were more prevalent in Lusaka, Eastern, Central and North Western Provinces.Cancers in females were more prevalent in Lusaka, Eastern, Central,

Southern, Western and Copperbelt Provinces. Figure 2 shows details of provincial distribution of cancers by sex.

Prevalence Rate Per 100,000 Population								
Province	Total	Males	Females					
Central	125	87	162					
Copperbelt	97	51	143					
Eastern	165	109	220					
Luapula	84	66	102					
Lusaka	281	212	349					
Northern	90	69	118					
Muchinga	78	59	97					
North West	104	89	118					
Southern	115	83	145					
Western	114	84	142					

Table 1: Distribution of cancers (all types) in Zambia by Province

Distribution of cancers by district

The distribution of cancers at district level is similar to the zonal pattern at provincial level. **Figure 3** shows the geographical distribution of cancers by district in Zambia. Some districts such as Mafinga, Ikelenge and Zimba were still part of the original districts namely Isoka, Mwinilunga and Kalomo respectively at the beginning of our research period hence are shown as combined districts in Table 2. The prevalence of cancers in the original districts reflects cancer prevalence in the new districts.

Luangwa has been the most cancer prevalent district in Zambia with the rate of 1014 per 100,000 population, seconded by Kabwe with the prevalence rate of 379 per 100,000 population. Lusaka has been the third district with prevalence rate of 311 per 100,000, Monze ranks fourth with the rate of 282 per 100,000, Mongu ranked fifth with prevalence rate of 260 per 100,000, Katete ranked sixth with prevalence rate of 229 and Chipata district ranked seventh with prevalence of 213 per 100,000 population. All these seven districts are from the southern zone.

The top four cancer prevalent districts in the northern zone are Kasempa with prevalence rate of 193 per 100,000, Kasama with prevalence rate of 168 per 100,000, Ndola with prevalence rate of 165 per 100,000 population. The least four cancer prevalent districts in Zambia were Lufwanyama with prevalence rate of 16 per 100,000, Itezhitezhi with prevalence rate of 16 per 100,000, Kazungula with prevalence rate of 14 per 100,000 and Chienge with prevalence rate of 12 per 100,000 population during the study period. Table 2 shows details of ranked prevalence of cancers by district per 100,000 population.

bioRxiv preprint doi: https://doi.org/10.1101/402628; this version posted August 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

District	Total	Males	Females	District	Total	Males	Females
Luangwa	1014	766	1257	Chinsali	90	52	127
Kabwe	379	251	499	Mkushi	88	57	120
Lusaka	311	233	387	Mwense	88	76	99
Monze	282	157	404	Luwingu	87	360	114
Mongu	260	176	337	Kitwe	82	52	113
Katete	229	142	313	Kaoma	80	62	96
Chipata	213	133	291	Sesheke	78	64	91
Kasempa	193	176	210	Isoka/ Mafinga	77	62	91
Kasama	168	118	217	Kafue	77	66	88
Ndola	165	76	252	Lukulu	77	37	114
Mansa	165	110	217	Chadiza	74	49	99
Choma	158	126	189	Samfya	70	74	67
Luanshya	156	77	234	Siavonga	70	49	90
Chongwe	155	123	187	Namwala	69	66	71
Petauke	153	102	202	Solwezi	65	60	71
Mumbwa	144	116	171	KapiriMposhi	61	32	89
Mbala	142	96	187	Chibombo	56	45	68
Livingstone	138	118	157	Nakonde	53	36	70
Zambezi	135	116	155	Sinazongwe	48	49	47
Mazabuka	126	86	165	Chama	48	47	48
Lundazi	120	86	153	Kalomo/ Zimba	45	34	47
Gwembe	113	80	145	Mpongwe	44	19	70
Mambwe	112	110	113	Nchelenge	43	30	55
Kalabo	111	91	130	Chililabombwe	40	19	61
Mufumbwe	110	97	124	Kalulushi	35	13	57
Mwinilunga/Ikelenge	107	73	141	Milenge	29	20	38
Nyimba	107	72	141	Mpulungu	29	14	43
Kabompo	106	97	116	Mungwi	27	19	35
Serenje	105	78	132	Kaputa	26	16	35
Chavuma	105	102	108	Shang'ombo	19	18	20
Mufulira	104	60	148	Chilubi	18	14	22
Mpika	102	82	122	Masaiti	17	17	17
Mporokoso	100	77	123	Lufwanyama	16	2	31
Kawambwa	95	78	110	Itezhitezhi	16	17	14
Senanga	93	84	101	Kazungula	14	13	16
Chingola	93	53	133	Chienge	12	9	15

Table 2: Ranked prevalence of cancers (all types) by district per 100,000 population

With a few exceptions of districts such as Luwingu, Sinazongwe and Samfya where cancers are more prevalent in males than in females, most districts in Zambia have high cancer prevalence in

bioRxiv preprint doi: https://doi.org/10.1101/402628; this version posted August 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

females than in males. The trend in the total district pattern (see Figure 3)remains the same as cancer distribution by sex at district level (see Figure 4). The detailed geographical distribution of cancers by sex at district level is shown in Figure 4.

Morbidity and mortality of cancers in Zambia

Cancer Type	Cases	Prevalence per	Male		Female		Both Sexes	
	Both Sexes	100, 000 pop.	Cases	Proportion (%)	Cases	Proportion (%)	Proportion (%)	
Cervix Uteri	7389	97.1			7389	53	34.3	
Kaposi's Sarcoma	2891	19.2	1759	23.3	1132	8.1	13.4	
Prostate	1651	22.1	1651	21.8			7.7	
Breast	1469	19.3	41	0.5	1428	10.2	6.8	
Eye	909	6.0	431	5.7	478	3.4	4.2	
Non-Hodgkin Lympoma	665	4.4	358	4.7	307	2.2	3.1	
Oesophagus	581	3.9	365	4.8	216	1.5	2.7	
Large Bowel	539	3.6	278	3.7	261	1.9	2.5	
Bladder	478	3.2	261	3.5	217	1.6	2.2	
Liver	460	3.1	283	3.7	177	1.3	2.1	
Other Skin	406	2.7	192	2.5	214	1.5	1.9	
Stomach	395	2.6	210	2.8	185	1.3	1.8	
Bone	252	1.7	130	1.7	122	0.9	1.2	
Vulva/Vagina	246	3.2			246	1.8	1.1	
Ovary	238	3.1			238	1.7	1.1	
Kidney	171	1.1	80	1.1	91	0.7	0.8	
Oral Cavity	168	1.1	95	1.3	73	0.5	0.8	
Penis	166	2.2	166	2.2			0.8	
Hodgkin Disease	151	1.0	99	1.3	52	0.4	0.7	
Melanoma of the skin	145	1.0	56	0.7	89	0.6	0.7	
Lung	135	0.9	90	1.2	45	0.3	0.6	
Brain, Nervous System	126	0.8	69	0.9	57	0.4	0.6	
Leukaemia	126	0.8	79	1	47	0.3	0.6	
Larynx	125	0.8	102	1.3	23	0.2	0.6	
Uterus	115	1.5			115	0.8	0.5	
Pancreas	102	0.7	61	0.8	41	0.3	0.5	
Corpus Uteri	95	0.6			95	0.7	0.4	
Thyroid	92	0.6	30	0.4	62	0.4	0.4	
Nasopharynx	85	0.6	51	0.7	34	0.2	0.4	
Myeloma	45	0.3	27	0.4	18	0.1	0.2	
Other Pharynx	42	0.3	29	0.4	13	0.1	0.2	
Others	1054	7.0	567	7.5	487	3.5	4.9	
Totals	21512	142.8	7560	100	13952	100	100	

Table 3: The Prevalence and proportions of cancers in Zambia, 2007 - 2014

During our study period from 2007 to 2014, a total of 21,512 cancer cases have been notified to ZNCR of which 7,560 (35.14%) were males and 13,952 (64.86%) were females. The actual notified cases could slightly be higher than these figures but due to missing or incomplete information, some cases could not be linked to districts and provinces of origin as we employed Geographical Information System (ArcGIS) version 10.3.1 to map cancers. Cervical cancer is the most prevalent cancer in Zambia followed by prostate cancer, breast cancer and Kaposi's sarcoma in that order. The prevalence rate of cervical cancer has been 97.1 per 100,000 females and represents 34.3% of all cancers in Zambia. In proportional terms, Kaposi's sarcoma ranks second and represents 13.3%, prostate cancer ranks third and represents 7.7% while breast cancer ranks fourth and represents 6.8%. Myeloma and Other Pharynx are the least prevalent among other cancers, each representing 0.2% of all cancers in Zambia. Table 3 shows details of prevalence and proportions of cancers in Zambia from 2007 to 2014.

Age specific rates, Standardised Incidence Rates (SIR) and the 95% confidence intervals (CI) for all cancers in Zambia are shown in **Table 4**. Rates were adjusted using the world standard population [23]. The standardised incidence ratesand 95% confidence intervalsfor the top four cancers in Zambia were: cervix uteri (186.3; 95% CI = 181.77 - 190.83), prostate (60.03; 95% CI = 57.03 - 63.03), breast (38.08; 95% CI = 36.0 - 40.16) and Kaposi's sarcoma (26.18;95% CI = 25.14 - 27.22).Peaks of age specific rates were in the age range 40 – 49 years for cervix uteri, 60 – 69 years for prostate cancer, and 40 – 49 years for breast cancer and 30 – 39 years for Kaposi's sarcoma.

CANCER TYPE	Age-sp	ecific Inc	idence Ra	te per 10	0,000 poj	pulation				SIR all	95% CI	
	0-9yr	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	ages	Lower	Upper
Cervix Uteri	0	0.07	5.5	23.41	49.68	46.11	39.78	14.09	7.67	186.3	181.77	190.83
Prostate	0	0	0	0.07	0.89	5.52	22.83	21.92	8.8	60.03	57.03	63.03
Breast	0	0.03	1.29	4.03	9.46	8.53	9.09	4.38	1.26	38.08	36	40.16
Kaposi's Sarcoma	0.35	0.65	3.58	7.66	7.42	3.17	1.82	0.64	0.88	26.18	25.14	27.22
Oesophagus	0.01	0.01	0.11	0.64	1.6	1.67	2.49	1.45	0.4	8.38	7.66	8.38
Eye	0.7	0.1	0.57	1.97	2.27	1.06	0.85	0.25	0.52	8.29	7.69	8.89
Bladder	0.01	0.02	0.12	0.34	0.78	1.36	2.94	1.41	0.46	7.45	6.74	8.16
Large Bowel	0	0.03	0.32	0.64	1.63	1.53	1.93	0.87	0.24	7.19	6.54	7.84
Non-Hodgkin Lympoma	0.31	0.45	0.51	0.8	1.46	1.33	1.28	0.48	0.2	6.82	6.23	7.41
Vulva/Vagina	0	0.01	0.31	0.8	1.61	1.22	1.23	0.46	0.3	5.94	5.14	6.74
Liver	0.02	0.09	0.27	0.56	1.21	1.22	1.3	0.83	0.36	5.86	5.28	6.44
Ovary	0.01	0.14	0.41	0.47	1.56	1.34	0.98	0.62	0.14	5.66	4.88	6.44
Stomach	0.01	0.02	0.12	0.41	0.93	1.23	1.53	1.04	0.32	5.61	5.02	6.2
Other Skin	0.05	0.08	0.28	0.53	0.81	1	1.26	0.69	0.38	5.07	4.53	5.61
Penis	0.02	0	0.03	0.26	0.98	1.28	1.38	0.58	0.41	4.93	4.13	5.73
Uterus	0	0.01	0.12	0.26	1.04	0.61	0.64	0.1	0.11	2.89	2.33	3.45
Corpus Uteri	0	0	0.06	0.12	0.42	0.85	1.15	0.2	0.07	2.87	2.26	3.48
Melanoma of the skin	0	0.02	0.02	0.1	0.28	0.48	0.88	0.39	0.09	2.26	1.87	2.65
Bone	0.1	0.38	0.25	0.22	0.36	0.22	0.52	0.12	0.07	2.25	1.92	2.58
Oral Cavity	0.04	0.05	0.08	0.13	0.36	0.55	0.63	0.34	0.07	2.24	1.87	2.61
Larynx	0.01	0	0.01	0.01	0.24	0.45	0.99	0.35	0.07	2.14	1.75	2.53
Lung	0	0	0.03	0.07	0.2	0.55	0.72	0.39	0.16	2.12	1.75	2.49
Pancreas	0	0	0.02	0.06	0.34	0.5	0.27	0.19	0.06	1.45	1.16	1.75
Hodgkin Disease	0.08	0.19	0.13	0.15	0.32	0.19	0.2	0.05	0.04	1.34	1.09	1.59
Thyroid	0	0.04	0.07	0.06	0.2	0.27	0.38	0.11	0.09	1.22	0.95	1.49
Kidney	0.45	0.09	0.01	0.1	0.13	0.12	0.11	0.07	0.07	1.16	0.95	1.37
Brain, Nervous System	0.16	0.08	0.1	0.08	0.23	0.2	0.18	0.09	0.02	1.13	0.9	1.36
Nasopharynx	0.03	0.05	0.04	0.11	0.21	0.25	0.29	0.02	0	0.99	0.75	1.23
Leukaemia	0.24	0.21	0.04	0.04	0.09	0.06	0.04	0.05	0	0.78	0.62	0.94
Other Pharynx	0	0.01	0.01	0.01	0.07	0.11	0.29	0.09	0.06	0.65	0.58	0.72
Myeloma	0	0.01	0.01	0.04	0.07	0.28	0.16	0.04	0.02	0.63	0.43	0.83
Others	0.35	0.52	0.84	1.07	1.98	2.47	2.88	1.32	0.68	12.11	11.29	12.93

Table 4: Standardised Incidence Rates (SIR) for all cancers in Zambia, 2007 - 2014

Like other diseases, cancers have been classified in the International Classification of Diseases known as ICD10. Table 5 shows details of ICD10 codes for cancers, their mortality and case fatality rates (CFR). Leukaemia (38.1%) and pancreatic cancer (36.3%)have the highest CFR among cancers in Zambia followed by lung cancer (33.3%) and brain, nervous system (30.2%).

bioRxiv preprint doi: https://doi.org/10.1101/402628; this version posted August 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Cancer Type	International Classification of Diseases (ICD10)	Cases	Deaths	Case Fatality Rate (%)
Leukaemia	C91-C95	126	48	38.1
Pancreas	C25	102	37	36.3
Lung	C33-C34	135	45	33.3
Brain, Nervous System	C70-C72	126	38	30.2
Kidney	C64	171	38	22.2
Liver	C22	460	91	19.8
Stomach	C16	395	78	19.7
Oesophagus	C15	581	113	19.4
Bladder	C67	478	90	18.8
Ovary	C56	238	44	18.5
Myeloma	C90	45	8	17.8
Nasopharynx	C11	85	15	17.6
Corpus Uteri	C54	95	16	16.8
Bone	C40-C41	252	40	15.9
Melanoma of the Skin	C43	145	21	14.5
Non-Hodgkin Lympoma	C82,C85,C96	665	89	13.4
Prostate	C61	1651	215	13.0
Large Bowel	C18-C21	539	68	12.6
Kaposi's Sarcoma	C46	2891	332	11.5
Thyroid	C73	92	10	10.9
Larynx	C32	125	12	9.6
Hodgkin Disease	C81	151	14	9.3
Uterus	C55	115	9	7.8
Breast	C50	1469	113	7.7
Cervix Uteri	C53	7389	543	7.3
Penis	C60	166	12	7.2
Oral Cavity	C00-C06	169	12	7.1
Other Skin	C44	406	25	6.2
Eye	C69	909	53	5.8
Vulva/Vagina	C51-C52	246	12	4.9
Other Pharynx	C09-C10, C12-C14	42	2	4.8
Others	C07-C08, C17,	1054	154	14.6
Totals		21512	2397	11.1

Table 5: Cancer classification and their mortality and CFR in Zambia, 2007 - 2014

Although CFR has been very high in Leukaemia,pancreatic cancer,lung cancer and cancers of the brain and nervous system, cancer mortality rates have been high in cervical cancer, prostate cancer, Kaposis's sarcoma, breast cancer and oesophageal cancer in that order. During our study

period 2007 to 2014, there were 543 cervical cancer deaths. Prostate cancer ranked second with 215 deaths followed by Kaposis' sarcoma with 332 deaths, then breast cancer and oesophagus cancer each with 113 deaths. Note: mortality rate for prostate cancer is higher than that of Kaposi's sarcoma despite the fact that Kaposi's sarcoma reported higher absolute number of 332 deaths while prostate cancer reported 215 deaths. The same principle applies for breast cancer and oesophagus cancer where breast cancer has a higher mortality rate than oesophageal cancer despite having the same absolute death figures. The reason is that the target population (denominator) for Kaposi's sarcoma and oesophageal cancer is the combined population figure for males and females while prostate cancer denominator is male population only or half the population of Kaposi's sarcoma. The smaller the denominator, the higher the mortality rate if the numerators remain equal.

Association between cancers and HIV in Zambia

Most cancers in Zambia are associated with HIV or HIV defining malignancies. HIV positive patients are more susceptible to cancers due to their compromised immunity. Results of the linear regression analysis and Pearson correlation indicated a strong association between cancer and HIV with *p*- value of 0.000 and correlation coefficient of 0.818. Cancer cases, HIV positive cases and percentage of HIV positive cancer cases are shown in Table 6.

DISCUSSION

Although cancers are widely distributed in Zambia, this study has established that cancers are more prevalent in the southern zone than the northern zone. The southern zone comprises the high prevalence region and medium prevalence region. Lusaka and Eastern provinces with very high cancer prevalent districts such as Luangwa, Katete, Chipata and Lusaka form the belt of the high prevalence region while Central, Southern and Western provinces with high cancer prevalent districts such as Kabwe, Mongu and Monze among others form the medium prevalence region. Although the northern zone has relatively low prevalence of cancers, there are notable districts such as Kasempa, Kasama, Ndola and Mansa with relatively high prevalence rates.

Some studies argue that the observed geographic variation in cancer distribution is due to differences in the availability of cancer screening and detection facilities [24-26]. Our study however has established that geographiclocation plays a big role in the pattern of cancer distribution in Zambia. This observation was made after mapping cancer cases based on patients' residential addresses. Distinct patterns were geographically displayed implying that geographic distribution plays a role. Cultural practices and lifestyles are other contributing factors to the observed trends of cancer distribution in Zambia. For instance, cervical cancer which is the most prevalent cancer accounting for 34.3% of all cancers in Zambia has been perpetrated by the culture of polygamist marriages (multiple sexual partners) which has been more pronounced in the southern zone than the northern zone. This culture has led to the spread of human papilloma virus (HPV) which causes cervical cancer [24].

bioRxiv preprint doi: https://doi.org/10.1101/402628; this version posted August 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

ICD10	Cancer Type	Cases	HIV positive	Percentage of HIV +	r	<i>p-</i> value
C00-C06	Oral Cavity	169	20	12		
C09-C10, C12-C14	Other Pharynx	42	4	10		
C11	Nasopharynx	85	22	26		
C15	Oesophagus	581	71	12		
C16	Stomach	395	41	10		
C18-C21	Large Bowel	539	60	11		
C22	Liver	460	43	9		
C25	Pancreas	102	6	6		
C32	Larynx	125	14	11		
C33-C34	Lung	135	12	9		
C40-C41	Bone	252	6	2		
C43	Melanoma of the skin	145	11	8		
C44	Other Skin	406	65	16		
C46	Kaposi's Sarcoma	2891	1734	60		
C50	Breast	1469	169	12		
C51-C52	Vulva/Vagina	246	58	24		
C53	Cervix Uteri	7389	1331	18	0.818	0.000
C54	Corpus Uteri	95	8	8		
C55	Uterus	115	14	12		
C56	Ovary	238	25	11		
C60	Penis	166	29	17		
C61	Prostate	1651	99	6		
C64	Kidney	171	4	2		
C67	Bladder	478	22	5		
C69	Eye	909	154	17		
C70-C72	Brain, Nervous System	126	10	8		
C73	Thyroid	92	8	9		
C81	Hodgkin Disease	151	31	21		
C82,C85,C96	Non-Hodgkin Lympoma	665	161	24		
C90	Myeloma	45	3	7		
C91-C95	Leukaemia	126	5	4		
C07-C08, C17,	Others	1054	97	9		
	Totals	21512	4337	20		

Table 6: Association between cancers and HIV in Zambia, 2007 – 2014

Our survey conducted between October 2017 and February 2018 across Zambia clearly showed that the southern zone of Zambia practices polygamist marriages (multiple sexual partners) far more than the northern zone hence the high prevalence of cervical cancer in the southern zone.

Similar trends in younger generations of European women have been observed and are thought to be due to increasing prevalence of high-risk HPV infection due to changing sexual practices [27,28].

By sex, cancers in Zambia affect more females than males in the ratio 64.86% to 35.14% (F/M = 1.85). This is mostly because of the high prevalence of cervical cancer in Zambian women. This study identified cervical cancer, prostate cancer, breast cancer and Kaposi's sarcoma as the top four most prevalent cancers in Zambia. Cervical cancer, with standardised incidence rate of 186.3 per 100,000 females has been the leading cause of morbidity and mortality among cancers in Zambian women. This is contrary to other studies which established that cervical cancer is the third leading cause of cancer-related deaths in developing countries which is not the case with Zambia [29]. According to age specific rates of cancers (see Table 4), cervical cancer peak has been observed in the age range of 40 - 49 years implying that this age group is the high risk group for cervical cancer in Zambia.

The prevalence of HPV infection has been 5% in North America and 21% in Africa [24] implying that the risk of contracting HPV in Africa is 4 times higher than in North America. In sub-Saharan Africa, cervical cancer incidence hasalso beeninfluenced by the high prevalence of HIV infection, which has been found to promote progression of cancerous lesions [30]. Cervical cancer incidence rates have decreased by as much as 4% annually, and 70% overall in developed countries where screening programs were introduced several decades ago [31,32]. The observed high prevalence rates of cervical cancer in Zambia is similar to observed trends in Zimbabwe, Uganda and some countries of Central and Eastern Europe [27,33,34].

Prostate cancer has been the second most prevalent cancer after cervical cancer and number one cancer in Zambian men with standardised incidence rate of 60.03 per 100,000 males. These results are similar to results of other studies which indicated that prostate cancer is the most prevalent cancer in men [29]. In this study, prostate cancer peak has been observed in the age range of 60 - 69 years. These results indicate that prostate cancer mostly occurs in ageing men. Age is a risk factor for prostate cancer.

Breast cancer ranks third among cancers in Zambia and second in women after cervical cancer. It has a standardised incidence rate of 38.08 per 100,000 females. Breast cancer peak has been observed in the age range of 40 - 49 years which is the productive age group for women; a double impact with cervical cancer in Zambia.On the global scale, breast cancer is the leading cause of cancer-related deaths among females. It is highest in the United States and Western Europe while Africa and Asia have low rates [29]. This explains why breast cancer is ranked third in Zambia. Higher breast cancer incidence in developed countries reflects the use of breast cancer screening as well as higher prevalence of breast cancer risk factors [35]. Risk factors for breast cancer include weight gain after age 18 years, excess body weight (for postmenopausal breast cancer), use of menopausal hormone therapy (MHT), physical inactivity, alcohol consumption, and reproductive and hormonal factors, such as a long menstrual history, recent

use of oral contraceptives, and nulliparity or later age at first birth [36,37].On the other hand, breastfeeding decreases the risk of breast cancer [37].

The distribution of some cancers in Zambia follows the trend of HIV epidemiology. This study has established a strong positive association between cancers and HIV with *p*-value of 0.000 and Pearson correlation coefficient of 0.818. These results indicate that HIV is a risk factor of cancers in Zambia. Some cancers such as Kaposi's sarcoma are HIV defining malignancies. Kaposi's sarcoma ranks fourth among cancers in Zambia with standardised incidence rate of 26.18 per 100,000 population. Kaposi's sarcoma peak has been observed in the age range of 30 - 39 years. This study has observed that Kaposi's sarcoma is more prevalent in males than in females (see Table 3). The incidence of Kaposi's sarcoma is higher in Sub-Saharan Africa than in developed countries. The endemic African form of Kaposi's sarcoma was reported in the 1960s [38], but with the emergence of HIV/AIDS, an atypical aggressive type has been reported in most African countries [39,40]. The incidence of Kaposi's sarcoma has increased simultaneously with the increased prevalence of HIV[41]. The high prevalence of HIV entails high resultant prevalence of cancers more especially Kaposi's sarcoma.

Although mortality rate has been high in cervical, prostate and breast cancers as well as oesophageal cancer and Kaposi's sarcoma, case fatality rate has been moderate in these cancers. This study observed high case fatality rate in Leukaemia, pancreatic cancer, lung cancer and cancers of the brain and nervous system. This means that Leukaemia and pancreatic cancer are more deadly than other cancers, the only holding factor being that their incidence rate is relatively low in Zambia.

This study had some limitations, firstly the missing information in the database made us leave some patients files as they could not be linked to districts of origin. Secondly, the Zambia National Cancer Registry has huge backlog of data due to understaffing. This brought about the adjustment of our study from 2007 - 2017 to 2007 to 2014 period. Lastly, registry based studies have challenges to provide precise data as registries data capturing system do not always suit all study designs. ZNCR does not fully capture risk factors for all cancers hence we could not critically determine all risk factors in this study.

In conclusion, the widespread distribution of cancers with high prevalence in the southern zone has been perpetrated by lifestyle and sexual culture as well as geography. The top seven most cancer prevalent districts in Zambia are Luangwa, Kabwe, Lusaka, Monze, Mongu, Katete and Chipata. Cervical cancer, prostate cancer, breast cancer and Kaposi's sarcoma are the top four most prevalent cancers as well as major causes of cancer related deaths in Zambia although Leukaemia and pancreatic cancer have the highest case fatality rate in Zambia. Most cancers in Zambia are HIV defining malignancies and their upward trend is due to the increase in HIV cases. Changing the lifestyle and sexual culture would greatly help in the prevention of rampant spread of HPV, HIV, HBV and EBVamong others which would result in the reduction of cancer

cases in Zambia. Furthermore, intensifying cancer screening and early detection countrywide would help to drastically reduce cancer prevalence in Zambia.

Competing Interests

Authors declare that they have no competing interests.

Authors' Contributions

MK designed the study, developed and programmed the model and drafted the manuscript.LL approved the model and provided technical support in analyses. MK and HS conceived the study. All authors read and approved the manuscript.

Acknowledgements

Compliments go tothe Research Ethics Committee of Institute of Urban Environment, Chinese Academy of Sciences, the University of Zambia Biomedical Research Ethics Committee and the National Health Research Authority of the Republic of Zambia for allowing the researchers to conduct a study in Zambia. The principal researcher is a PhD candidate at the Institute of Urban Environment, university of Chinese Academy of Sciences, 1799 Jimei Road, Xiamen, 361021, PR China under the scholarship of UCAS.

REFERENCES

- 1. Kachroo S, Etzel CJ. Decreasing the cancer burden in developing countries: concerns and recommendations. Eur. J. Cancer Care (Engl) 2009; 18: 18-21.
- 2. Sener SF, Grey N. The global burden of cancer. J. Surg. Oncol. 2005;92:1-3.
- 3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127:2893-2917.
- 4. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31: 100-110.
- 5. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national agesex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. Published correction appears in Lancet. 2013;381(9867):628.

- 7. 3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349(9061):1269–1276.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. GLOBOCAN 2012 v1.0, Lyon, France: International Agency for Research on Cancer 2013;Vol. 1.
- 9. Vorobiof DA, Abratt R. The cancer burden in Africa. S. Afr. Med. J. 2007;97:937-939.
- 10. Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases--where worlds meet. N. Engl. J. Med.2010;363: 1196-1198.
- 11. Bray F, Moller B. Predicting the future burden of cancer. Nat. Rev. Cancer 2006;6:63-74.
- 12. Pisani P, Parkin DM, Muñoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 387-400.
- 13. Ngoma T. World Health Organization cancer priorities in developing countries. Ann. Oncol. 2006; 17 (Suppl 8):viii9-viii14.
- 14. Reeler AV, Mellstedt H (2006). Cancer in developing countries: challenges and solutions. Ann. Oncol. 2006; 17 (Suppl 8):viii7-viii8.
- 15. Fontham ET. Infectious diseases and global cancer control. CA Cancer J. Clin. 2009;59: 5-7.
- 16. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006; 118: 3030-3044.
- IARC Working Group. Proceedings on the Evaluation of Carcinogenic Risks to Humans. Epstein - Barr virus and Kaposi's Sarcoma Herpesvirus/ Human Herpesvirus 8. Lyon, France, 17-24. 100 J. Public Health Epidemiol. June 1997. IARC Monogr. Eval. Carcinog. Risks Hum. 1997; 70:1–492.
- 18. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, Hainaut P, Hall AJ, Whittle H, Montesano R. The Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatol. 2004; 39:211-219.
- 19. Blankfield RP. *Helicobacter pylori* infection and the development of gastric cancer. N. Engl. J. Med. 2002; 346:65-67.
- 20. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
- 21. Knowles DM. Etiology and pathogenesis of AIDS-related non Hodgkin's lymphoma. Hematol. Oncol. Clin. North Am. 2003; 17: 785-820.

- 22. Zambia latitude and longitude map. Source: http://www.mapsofworld.com/lat long/zZambialat-long.html.
- 23. IARC. *World Standard Population*. 2010; Available at: http://www.dep.iarc.fr/WHOdb/glossary.htm. Last accessed Jan 2015.
- 24. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis2010;202:1789–99.
- 25. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12–23.
- 26. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013;49:3262–73.
- 27. Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013;31 Suppl 7:H32–45.
- 28. Maver PJ, Seme K, Korac T, Dimitrov G, Dobrossy L, Engele L, et al. Cervical cancer screening practices in central and eastern Europe in 2012. Acta Dermatovenerol Alp Pannonica Adriat 2013;22:7–19.
- 29. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. [cited 2015 July 30]. Available from: <u>http://globocan.iarc.fr</u>
- 30. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013;31 Suppl 5:F32–46.
- 31. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677–86.
- 32. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755–63.
- 33. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000;82:1585–92.
- Chokunonga E, Borok M, Chirenje Z, Nyakabau A, Parkin D. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer 2013;133:721–9.

- 35. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 2005;34:405–12.
- 36. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013;105:526–35.
- 37. Schottenfeld D, Fraumeni JF Jr.Colditz GA, Baer HJ, Tamimi RM. Breast cancer. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press 2006; p. 995–1012.
- 38. Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br. J. Cancer 1998; 78:1521-1528.
- 39. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int. J. Cancer 1993; 54:26-36.
- 40. Bassett MT, Chokunonga E, Mauchaza B, Levy L, Ferlay J, Parkin DM. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int. J. Cancer 1995; 63:29-36.
- 41. Chintu C, Athale UH, Patil PS. Childhood cancers in Zambia before and after the HIV epidemic. Arch. Dis. Child. 1995; 73:100-104.







